Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent

The epidermal growth factor receptor (EGFR) family has been validated as a successful antitumor drug target for decades. Known EGFR inhibitors were exposed to distinct drug resistance against the various EGFR mutants within non-small-cell lung cancer (NSCLC), particularly the T790M mutation. Althoug...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei, Ning, Jin-Feng, Meng, Qing-Wei, Hu, Jing, Zhao, Yan-Bin, Liu, Chao, Cai, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517520/
https://www.ncbi.nlm.nih.gov/pubmed/26229444
http://dx.doi.org/10.2147/DDDT.S85357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517520/
https://www.ncbi.nlm.nih.gov/pubmed/26229444
http://dx.doi.org/10.2147/DDDT.S85357

Ejemplares similares